ZBH Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 14.45%. Zimmer Biomet Holdings's return on equity of 7.29% beat Boston Scientific's return on equity of 9.57%.

Zimmer Biomet Holdings has a consensus price target of $107.50, signalling upside risk potential of 14.97%. On the other hand Boston Scientific has an analysts' consensus of $117.55 which suggests that it could grow by 13.43%. Given that Zimmer Biomet Holdings has higher upside potential than Boston Scientific, analysts believe Zimmer Biomet Holdings is more attractive than Boston Scientific.

Zimmer Biomet Holdings has a beta of 0.710, which suggesting that the stock is 28.957% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.134%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.03%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.9B, which are smaller than Boston Scientific quarterly revenues of $4.7B. Zimmer Biomet Holdings's net income of $182M is lower than Boston Scientific's net income of $674M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.69x while Boston Scientific's PE ratio is 75.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.46x versus 8.79x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Edwards Lifesciences has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 25.34%. Zimmer Biomet Holdings's return on equity of 7.29% beat Edwards Lifesciences's return on equity of 46.91%.

Zimmer Biomet Holdings has a consensus price target of $107.50, signalling upside risk potential of 14.97%. On the other hand Edwards Lifesciences has an analysts' consensus of $81.01 which suggests that it could grow by 5.18%. Given that Zimmer Biomet Holdings has higher upside potential than Edwards Lifesciences, analysts believe Zimmer Biomet Holdings is more attractive than Edwards Lifesciences.

Zimmer Biomet Holdings has a beta of 0.710, which suggesting that the stock is 28.957% less volatile than S&P 500. In comparison Edwards Lifesciences has a beta of 1.108, suggesting its more volatile than the S&P 500 by 10.836%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.03%. Edwards Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Edwards Lifesciences pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.9B, which are larger than Edwards Lifesciences quarterly revenues of $1.4B. Zimmer Biomet Holdings's net income of $182M is lower than Edwards Lifesciences's net income of $358M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.69x while Edwards Lifesciences's PE ratio is 11.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.46x versus 8.28x for Edwards Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 9.84%. Zimmer Biomet Holdings's return on equity of 7.29% beat Steris PLC's return on equity of 9.5%.

Zimmer Biomet Holdings has a consensus price target of $107.50, signalling upside risk potential of 14.97%. On the other hand Steris PLC has an analysts' consensus of $263.10 which suggests that it could grow by 10.43%. Given that Zimmer Biomet Holdings has higher upside potential than Steris PLC, analysts believe Zimmer Biomet Holdings is more attractive than Steris PLC.

Zimmer Biomet Holdings has a beta of 0.710, which suggesting that the stock is 28.957% less volatile than S&P 500. In comparison Steris PLC has a beta of 0.923, suggesting its less volatile than the S&P 500 by 7.704%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.03%. Steris PLC offers a yield of 0.96% to investors and pays a quarterly dividend of $0.57 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Steris PLC pays out 35.77% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.9B, which are larger than Steris PLC quarterly revenues of $1.5B. Zimmer Biomet Holdings's net income of $182M is higher than Steris PLC's net income of $145.7M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.69x while Steris PLC's PE ratio is 38.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.46x versus 4.32x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of -30.29%. Zimmer Biomet Holdings's return on equity of 7.29% beat Treace Medical Concepts's return on equity of -47.17%.

Zimmer Biomet Holdings has a consensus price target of $107.50, signalling upside risk potential of 14.97%. On the other hand Treace Medical Concepts has an analysts' consensus of $10.02 which suggests that it could grow by 64.48%. Given that Treace Medical Concepts has higher upside potential than Zimmer Biomet Holdings, analysts believe Treace Medical Concepts is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 0.710, which suggesting that the stock is 28.957% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.03%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.9B, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. Zimmer Biomet Holdings's net income of $182M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.69x while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.46x versus 1.80x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.